Skip to main content

Masashi has a background in biomedical and life sciences and specialises in international business development and strategic network building.

Masashi joined Oxentia as a senior consultant in November 2019. He supports industry, government agencies and university clients with their early-stage technology commercialisation programmes. Masashi helps clients with business development and innovation strategy; technology scouting; assessing commercial opportunities; valuation and market analysis. He has worked with clients in Biomedical and life sciences, chemical, software and higher-education sectors.

Masashi has over 20 years of business development, product marketing and commercial operations management experience, he worked for global corporates including Hitachi Chemical and Thermo Fisher Scientific, before co-founding Biospire Japan, an international consultancy specialising in early stage technology management.

Masashi is an active figure in the Japanese innovation ecosystem; he is an advisor for MEDISO, the Medical Innovation Support Office, a Japanese government funded programme supporting medical start-ups; and works closely with Link-J, the Life Sciences Innovation Network Japan. Masashi is passionate about promoting collaboration between UK and Japanese start-ups and investors, unlocking the commercialisation potential of cutting-edge science and technology research.

Outside of Oxentia, Masashi enjoys walking and travelling with his three daughters. He used to play volleyball in a British national league.


  • Technology commercialisation
  • Strategic business development
  • Innovation networks
  • Entrepreneurship
  • New product development
  • Incubator and accelerator programme design and delivery
  • Biomedical and Life Sciences


  • Ph.D. in Biomedical and Life Sciences, University of Surrey. (2001)
  • BSc, Faculty of Agriculture Sciences. (1997)
Connect on LinkedIn

Contact Me

This website site uses cookies to improve your browsing experience. By continuing to use this site, you are agreeing to our use of cookies. Review our privacy policy.

Accept and close